Janice Cowden, MBC Patient Advocate, shared on LinkedIn:
“Honored to have contributed as a co-author on this newly published White Paper in Clinical Pharmacology and Therapeutics examining how prescription drug information is generated, communicated, and interpreted.
Over the past decade, we’ve seen remarkable progress in oncology, especially in metastatic breast cancer. More treatment options mean more hope for patients, but they also mean more complex decisions.
As someone diagnosed with metastatic breast cancer, I’ve witnessed firsthand how difficult it can be to weigh potential benefits against toxicities, quality of life, and uncertainty. Patients deserve clear, balanced, transparent information that supports truly informed, shared decision making. This paper explores important information gaps and offers recommendations for strengthening the prescription drug information ecosystem across patients, clinicians, industry, payers, and regulatory agencies.
As treatment options continue to expand, ensuring patients have balanced, transparent information will be just as important as developing the next breakthrough therapy.
I’m grateful to have collaborated with such an outstanding multidisciplinary group on a topic that I believe will become increasingly important as drug development continues to accelerate.”
Title: Navigating the Prescription Drug Information System
Authors: Irina V. Wang, Courtney Davis, Robin Forrest, Avi Cherla, Maximilian Siebert, Janice Cowden, Sophia Walker, Tamar Krishnamurti, Florence T. Bourgeois, Steven Woloshin, Anita K. Wagner, Huseyin Naci
Read the full article.
You might be interested in:
